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Abstract
Background: The over-expression of transforming growth factor β-1(TGF-β1) has been reported to cause hydrocephalus, glia
activation, and vascular amyloidβ (Aβ) deposition in mouse brains. Since these phenomena partially mimic the cerebral amyloid
angiopathy (CAA) concomitant to Alzheimer's disease, the findings in TGF-β1 over-expressing mice prompted the hypothesis
that CAA could be caused or enhanced by the abnormal production of TGF-β1. This idea was in accordance with the view that
chronic inflammation contributes to Alzheimer's disease, and drew attention to the therapeutic potential of anti-inflammatory
drugs for the treatment of Aβ-elicited CAA. We thus studied the effect of anti-inflammatory drug administration in TGF-β1-
induced pathology.
Methods:  Two-month-old TGF-β1 mice and littermate controls were orally administered pioglitazone, a peroxisome
proliferator-activated receptor-γ agonist, or ibuprofen, a non steroidal anti-inflammatory agent, for two months. Glia activation
was assessed by immunohistochemistry and western blot analysis; Aβ precursor protein (APP) by western blot analysis; Aβ
deposition by immunohistochemistry, thioflavin-S staining and ELISA; and hydrocephalus by measurements of ventricle size on
autoradiographies of brain sections. Results are expressed as means ± SD. Data comparisons were carried with the Student's T
test when two groups were compared, or ANOVA analysis when more than three groups were analyzed.
Results: Animals displayed glia activation, hydrocephalus and a robust thioflavin-S-positive vascular deposition. Unexpectedly,
these deposits contained no Aβ or serum amyloid P component, a common constituent of amyloid deposits. The thioflavin-S-
positive material thus remains to be identified. Pioglitazone decreased glia activation and basal levels of Aβ42- with no change
in APP contents – while it increased hydrocephalus, and had no effect on the thioflavin-S deposits. Ibuprofen mimicked the
reduction of glia activation caused by pioglitazone and the lack of effect on the thioflavin-S-labeled deposits.
Conclusions: i) TGF-β1 over-expressing mice may not be an appropriate model of Aβ-elicited CAA; and ii) pioglitazone has
paradoxical effects on TGF-β1-induced pathology suggesting that anti-inflammatory therapy may reduce the damage resulting
from active glia, but not from vascular alterations or hydrocephalus. Identification of the thioflavin-S-positive material will
facilitate the full appraisal of the clinical implication of the effects of anti-inflammatory drugs, and provide a more thorough
understanding of TGF-β1 actions in brain.
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Background
Transforming growth factor-β1 (TGF-β1) is a multifunc-
tional cytokine implicated in developmental processes,
immune host defense, and injury repair [for review, [1]].
TGF-β1 contributes to the resolution of injuries by inhib-
iting local inflammation, and by stimulating the synthesis
and deposition of matrix components leading to the
reconstitution of the basal membrane in the final stages of
angiogenesis. A paradoxical feature of TGF-β1 is that,
when produced in excess or in the absence of counter-reg-
ulatory elements, it can become pro-inflammatory,
induce abnormal vascular growth, and thus be detrimen-
tal [2]. This occurs in the mouse brain, where the trans-
genic over-expression of TGF-β1 in astrocytes causes
chronic astrocytosis and microglia activation, as well as
fibrosis – i.e. increased production of matrix proteins and
abnormal thickening of vascular basal membranes – and
endothelial cell atrophy [3,4]. The mice develop hydro-
cephalus [3], revealing an alteration of cerebrospinal fluid
(CSF) dynamics – probably due to clearance obstruction
– and present, at one year of age, a reduction in brain
blood flow and metabolism, signs of vascular and neuro-
nal dysfunction [5].
Another abnormality reported in TGF-β1 over-expressing
brains was the vascular and meningeal deposition of
endogenous mouse amyloidβ (Aβ), as well as of human
Aβ when TGF-β1 was over-expressed together with a
mutated form of the human Aβ precursor protein (APP)
[6,7]. The vascular deposition was a likely consequence of
the fibrosis, since components of the extracellular matrix
have been shown to trigger the fibrillation of Aβ proteins
[8]. Vascular Aβ deposition is often seen postmortem in
individuals with Alzheimer's disease as cerebral amyloid
angiopathy (CAA), which appears to be an important
pathogenic factor in the disease [9-12]. The detection of
TGF-β1 and fibrosis in vessels bearing Aβ deposits in
human brains [6], together with the β amyloidogenic role
of TGF-β1 in mouse models, led to the hypothesis that Aβ-
related CAA could be caused or enhanced by the aberrant
production of TGF-β1 [6]. This idea was in accordance
with the view that chronic inflammation contributes to
the pathogenesis of Alzheimer's disease [for review, [13]],
as supported by: i) epidemiological studies showing that
the use of non steroidal anti-inflammatory drugs
(NSAIDs) like ibuprofen delays the onset of Alzheimer's
disease [14]; and ii) studies in APP mice showing that
treatment with ibuprofen reduces gliosis, microglia activa-
tion, interleukin-1β production, and amyloid plaque bur-
den, and improves cognition [15,16]. The TGF-β1 over-
expressing mice thus emerged as a model to gain insight
into the relationship between chronic inflammation and
vascular Aβ deposition, and to evaluate the therapeutic
potential of drugs.
We sought to determine whether pioglitazone, a novel
anti-inflammatory drug, reduces glia activation, APP
expression, and Aβ production and deposition in TGF-β1
over-expressing mice. For comparison, we tested the effect
of ibuprofen on some of these parameters since this drug
is beneficial in patients with Alzheimer's disease and APP
mouse models. Pioglitazone is a thiazolidinedione (TZD)
drug and an agonist of the peroxisome proliferator-acti-
vated receptor gamma (PPARγ), a nuclear receptor that
plays a key role in the regulation of glucose and lipid
metabolism in non cerebral tissues. The rationale for the
use of pioglitazone stems from: i) the anti-inflammatory
effect of PPARγ in vivo and in vitro [17-19]; ii) the commer-
cial availability and safety record of pioglitazone and
other TZDs, which are currently in use for the treatment of
type 2 diabetes; and iii) the fact that pioglitazone, unlike
ibuprofen, does not cause gastric problems after pro-
longed treatment and thus it would be better suited for
chronic use. TZD-PPARγ agonists can block in mice the
development of experimental allergic encephalomyelitis
[20], and reduce the degeneration of dopaminergic neu-
rons caused by methyl-4-phenyl-1,2,3,6-tetrahydropyrid-
ine (MPTP) [ref [21]. In both cases, the protective actions
of TZDs have been attributed to their anti-inflammatory
capacities. A review of the therapeutic potential and mech-
anisms of action of TZDs in Alzheimer's disease has been
presented elsewhere [22].
The mice under study showed astrocyte and microglia
activation, hydrocephalus and thioflavin-S-positive
deposits. A two-month treatment with pioglitazone
reduced glia activation, but it increased hydrocephalus
unexpectedly, while it had no effect on the thioflavin-S-
positive deposits. Immunohistochemical analyses and
ELISAs failed to confirm the presence of Aβ in such depos-
its, despite an increase in Aβ40 levels detected at 9
months. These findings contradict the view that TGF-β1
over-expressing mice are a model of Aβ-elicited CAA, and
reveal paradoxical effects of pioglitazone on TGF-β1-
induced chronic inflammation whose clinical relevance is
discussed.
Material and methods
Generation of mice and anti-inflammatory treatment
The study was carried out in heterozygous C57BL/6 mice
genetically modified to produce a constitutively active
form of TGF-β1 under the control of the GFAP promoter.
The mice were derived from the heterozygous line T65,
generated similarly to the line T64 on a BALB/c back-
ground [3], and changed to C57BL/6 by successive cross-
ings. APP mice over-expressing the human V711F
mutation [23] were used as positive controls for immuno-
histochemistry. Animal care was carried out according to
the European Community's regulations, the principles ofJournal of Neuroinflammation 2004, 1:11 http://www.jneuroinflammation.com/content/1/1/11
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which agree with the National Institutes of Health guide
for the care and use of laboratory animals.
TGF-β1 over-expressing mice and littermate controls were
sacrificed at 2, 4 and 9 months of age to assess the evolu-
tion over time of inflammation and vascular Aβ deposi-
tion. Treatment with the anti-inflammatory drugs started
at 2 months of age, soon after weaning, and was carried
out for 2 months.
Ibuprofen was purchased from Sigma, and pioglitazone,
manufactured by Takeda Pharmaceuticals, was obtained
from a local pharmacy. The drugs were pulverized, and
mixed with Purina chow to give concentrations of 120
ppm and 375 ppm of pioglitazone and ibuprofen, respec-
tively. Mice were allowed free access to the chow. Neither
pioglitazone nor ibuprofen caused detectable weight
changes, or affected the amount of food consumed by the
mice. The animal weights, monitored in 42 animals, were
23.4 ± 4.2 g at the start of the treatments, and 25.2 ± 4.6 g
at the end. The amount of food consumed, expressed in g/
mouse/week, was: in the control group, 30.8 ± 3.8 (n =
17); in the ibuprofen group, 31.0 ± 6.4 (n = 11); and in
the pioglitazone group, 25.9 ± 4.2 (n = 14). Values are the
means ± SD. These values translate to a daily dosing of
approximately 18 mg/kg of pioglitazone, and 60 mg/kg of
ibuprofen.
Immunohistochemistry
The mice were sacrificed under anesthesia. The brains
were taken out of the skulls, and fixed by submersion in
4% paraformaldehyde in 0.1 M phosphate buffer for 24
hours at 4°C. The brains were transferred to 10% sucrose
in 0.1 M phosphate buffer for 24 hours at 4°C, snap fro-
zen in isopentane at -40°C, and kept at -80°C until fur-
ther use. Brain sections (35 µm) were cut in a cryostat and
collected in phosphate-buffered saline (PBS). The immu-
nohistochemistry was carried out on free-floating sec-
tions. The sections were incubated 15 min in 3% H2O2/
20% methanol to inactivate endogenous peroxidase activ-
ity. The sections were blocked with 0.5% bovine serum
albumin (BSA) in PBS, and incubated with primary anti-
bodies in PBS containing 0.2% Triton X-100 and 0.1%
BSA. The incubations were performed overnight at 4°C
with gentle shaking. After several washes in PBS, the sec-
tions were incubated with biotinylated secondary anti-
bodies (1:200, Vector Laboratories, Burlingame, CA) for
30 min at room temperature. The staining was visualized
by the biotin-avidin-peroxidase method (Elite Kit, Vector
Laboratories, Burlingame, CA) using diaminobenzidine
as the chromogen. To reveal Aβ deposits, the sections were
incubated in 80% formic acid for 5 min before blocking
with BSA. The primary antibodies used were: rabbit anti-
mouse GFAP (1: 1000, Sigma), rat anti-mouse Mac-1 (1:
250, Serotec, Oxford, United Kingdom), rabbit anti-
human Aβ40 FCA40 (1: 500, courtesy of Frederic
Checler); mouse anti Aβ clone 4G8 (1: 500, Signet, Ded-
ham, MA); and sheep anti-mouse serum amyloid P com-
ponent (SAP, 1: 500, Calbiochem, San Diego, CA).
Analysis of microglia activation
Microglia activation was assessed in the hippocampus by
measuring the soma surfaces of Mac-1 positive cells with
the image analysis system VisioScan (BIOCOM, Les Ulis,
France), following a variation of the method described by
Breidert et col. [21]. Brain sections were analyzed at a 50×
magnification under high contrast. A minimum of 100
microglia cells were examined per brain. Each cell was
scanned to find the plane containing the largest soma sur-
face. Figure 1G,1H,1I shows the contours of microglia
soma in different states of activation.
Thioflavin-S labeling
The number of thioflavin-S-containing vessels was
counted in three levels of the hippocampus (the distance
from Bregma is indicated in parentheses): i) rostral (-1.75-
to -2.5 mm), ii) intermediate (-2.5 to -3.25 mm), and iii)
dorsal (-3.25 to -4.5 mm). Coronal brain sections were
mounted on slides, air-dried, and incubated with 1%
thioflavin-S (Sigma) for 10 min, followed by short rinses
in 80–90% alcohol, and a final rinse in H2O. The sections
were mounted in Vectastain fluorescent mounting media,
and the staining visualized with UV light or FITC filters. In
the case of branched vessels each branch was counted as
"one". The thioflavin-S-positive vascular density per hip-
pocampus level was the average of 4 sections.
Western blots
The hippocampi were snap frozen in isopentane cooled
on dry ice, and stored at -80°C. Brain tissue was homoge-
nized by passage through 18-, 21-, and 26-G syringes, in a
buffer containing 50 mM Tris pH 8.0, 150 mM NaCl, 1
mM EDTA, 1% NP40, and protease inhibitors. The
homogenates were left 20 min on ice, and centrifuged at
15,000 × g for 15 min. The supernatants were processed
for PAGE-SDS electrophoresis. Proteins were then trans-
ferred to PVDF membranes (BioRad) by semi-dry electro-
phoresis. The membranes were blocked in 10% milk in 10
mM Tris/150 mM NaCl containing 0.1% Tween-20 (TBS)
and incubated overnight in TBS containing the primary
antibodies. The membranes were incubated with HRP-
conjugated IgGs for 1 hour. Washes between steps were
carried out with TBS. The bands were visualized with
enhanced chemiluminescence reagents (New England
Nuclear, MA, USA), and exposure to X-ray films. Three
antibodies were used: rat anti-mouse GFAP (1: 5000,
clone MAB 2.2B10, provided by Virginia Lee); mouse anti-
APP C-terminus (1: 1000, clone C1/6.1, ref 24), and rab-
bit anti-human actin (1: 500, Sigma, Santa Cruz, CA) to
assure equal loading of protein. HRP-conjugatedJournal of Neuroinflammation 2004, 1:11 http://www.jneuroinflammation.com/content/1/1/11
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secondary antibodies were purchased from Vector Labs.
For quantitative assessment of bands, the
autoradiographs were scanned and analyzed with Image J
from the National Institutes of Health.
ELISA
Hippocampi were homogenized individually by passage
through 18-26-G syringes in 0.25 mL of buffer (250 mM
sucrose, 20 mM Tris base, 1 mM EDTA, and 1 mM EGTA)
in the presence of protease inhibitors. The homogenates
were extracted with a diethylamine (DEA)/NaCl solution
as previously described [25], and processed for sandwich
ELISA measurements using monoclonal antibodies JRF/
cAβ40/10 and JRF/cAβ42/26, which specifically recognize
the carboxyl-terminals of mouse Aβ40 and Aβ42, respec-
tively and JRF/rAβ1-15/2, which binds to the N-terminus
of murine Aβ. Applications of this ELISA have been previ-
ously described elsewhere [24-26].
Mac-1 immunoreactivity in the hippocampus Figure 1
Mac-1 immunoreactivity in the hippocampus. The age, phenotype and treatment of the animals are indicated in the upper right 
corners. T-: control and T+: TGF-β1 mice; PIO: treated with pioglitazone for 2 months; 4 m and 9 m: 4 and 9-month-old mice. 
Each row shows images taken at increasing magnifications (bars are 50 µM). Microglia cells were "activated" in TGF-β1 mice at 
4 months, revealed by increased Mac-1 immunoreactivity, retraction of processes, and increased soma size (compare B to A 
and E to D). Microglia activation decreased with age (compare C to B) and with PIO (compare F to E). G-I are high magnifica-
tion images of single microglia cells. The insets illustrate the soma surfaces as determined for the quantification of microglia 
activation. DG: dentate gyrus; HiF: hippocampal fissure.
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Evaluation of ventricle size
The degree of hydrocephalus was assessed in coronal sec-
tions of 20 µm thickness obtained from fresh-frozen
brains processed for 14C-deoxyglucose autoradiography
for a parallel study. The areas of the lateral ventricles were
measured at three levels using VisioLab software (BIO-
COM): i) rostral, at bregma +1.1 (the anatomical refer-
ence was the genu of the corpus callosum); ii)
intermediate, at bregma -0.7 mm (references were the
anterior fimbria hippocampus, the dorsal 3rd ventricle and
the subfornical organ); and iii) caudal, at bregma -2.5 mm
(posterior ventral end of the 3rd ventricle and the dorsov-
entral hippocampal horn). An average ventricle surface
per animal was calculated from the three values.
Statistical analysis
Results are expressed as means ± SD. Data comparisons
were carried with the Student's T test when two groups
were compared, or one or two-way ("treatment" versus
"genotype") ANOVA analysis followed by the Bonferroni
test when more than three groups were analyzed. Differ-
ences were considered significant in the 95% confidence
interval when p < 0.05. Statistical analyses were per-
formed with Prism Graphpad version 3.0 software.
Results
Age-dependence of glia activation and thioflavin-S-labeled 
deposits
Microglia cells were activated in TGF-β1 mice 2–4 months
old, mostly in the hippocampus. The cells showed
increased Mac-1 immunoreactivity, shortening and thick-
ening of processes, and enlargement of somas (Fig 1B,1E
and Fig 2). In control animals nearly all of the somas were
smaller than 150 µm2, whereas in TGF-β1 animals the
somas ranged between 100–400 µm2 (Fig 2A). We hence
defined "activated microglia" as cells with somas larger
than 150 µm2  irregardless of the intensity of Mac-1
expression.
The microglia were clearly activated (60% of all cells) at 2
months of age, the earliest time analyzed (Fig 2B). The
extent of activation was comparable at 4 months, but
decreased to 20% at 9 months (p < 0.01) (Fig 1C and Fig
2B).
TGF-β1 animals also had astrocytosis at all ages analyzed,
defined as increased GFAP immunoreactivity (Fig 3), and
increased GFAP protein content assessed by Western blot
analysis (Fig 4). The astrocytosis was detected throughout
the brain, but it characteristically affected the hippocam-
pus in particular the dentate gyrus.
In TGF-β1 animals, but not in control mice (Fig 5A,5C),
thioflavin-S labeled meninges and vessels of 10–20 µm
diameter concentrated primarily around the hippocampal
fissure (Fig 5B) and, on occasion, in larger penetrating ves-
sels directly originating from the pial vasculature (Fig 5D).
The density of thioflavin-positive vessels was higher in
rostral hippocampus and decreased caudally by 30% (Fig
6). Both meningeal and vascular deposits were evident at
2 months (Fig 6A). The density of thioflavin-S positive
vessels increased by 40% at 4 months, and did not change
thereafter (Fig 6A), indicating that the thioflavin-S-
labeled material accumulated early, and achieved a
steady-state by 4 months.
Comparison of the thioflavin-labeled material in vessels
from TGF-β1 and APP mice revealed two differences (Fig
5E,5F,5G). First, in APP mice the deposition affected long
vessels in the cortical parenchyma, while in TGF-β1 mice
the labeled vessels were shorter, frequently branched, and
localized to the hippocampal fissure. Secondly, the thio-
flavin-S deposits appeared to have spread over the vessels
in patches in APP brains, while deposits appeared
smoother and more uniformly covered entire vascular
stretches in TGF-β1 mice. This strongly suggests a different
composition of the vascular deposits in APP and TGF-β1
transgenic mice.
Effect of anti-inflammatory drugs on glia activation and 
vascular amyloid deposition
Ibuprofen or pioglitazone treatments were started at 2
months of age and continued for 2 months. Two reasons
justified the length of the treatments: i) we had estab-
lished that the largest change detected in vascular depos-
its, as assessed with thioflavin-S, took place before 4
months of age; and ii) since Mac-1 expression dramati-
cally decreased with age, a longer treatment would have
potentially complicated the assessment of whether the
drugs had efficiently inhibited inflammation.
Both ibuprofen and pioglitazone effectively reversed the
TGF-β1-induced microglia activation. Pioglitazone
reduced the number of activated microglia by 40% (p <
0.01), and ibuprofen by 70% (p < 0.001) (Fig 2C).
Accordingly, Mac-1 expression and soma sizes were
reduced, and the cellular processes recovered some of the
diffuse pattern that characterizes resting microglia (Fig
1D,1E,1F). The anti-inflammatory treatment also reduced
the astrogliosis (Fig 3C,3D and Fig 4A). By contrast, nei-
ther pioglitazone nor ibuprofen changed the density of
thioflavin-S-positive vessels (Fig 6B). This suggests that
none of the drugs interfered with the vascular deposition
that occurred between 2 and 4 months of age.
Measurement of Aβ and APP
Aβ production was assessed by ELISA and immunohisto-
chemistry. It should be stressed that the antibodies used in
both procedures, FCA40 [27,28], 4G8 [29], JRF/cAβ40/
10, JRF/cAβ42/26, JRF/rAβ1-15/2 [24-26] recognizeJournal of Neuroinflammation 2004, 1:11 http://www.jneuroinflammation.com/content/1/1/11
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Quantification of microglia activation Figure 2
Quantification of microglia activation. A) Distribution of microglia according to soma sizes in 4-month-old control and TGF-β1 
mice fed for 2 months with control chow, or chow containing pioglitazone or ibuprofen; B) Evolution of microglia activation 
with age; C) Effect of anti-inflammatory drugs. "Activated microglia" were cells with somas larger than 150 µm2. The values are 
the means ± SD; (**) p < 0.01; (***) p < 0.001, one-way ANOVA analysis, Bonferroni post hoc test. N = 2 for 2-month-old 
mice, and N = 4–6 for 4 or 9-month-old mice.
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mouse Aβ and hence should detect endogenous mouse Aβ
in TGF-β1 mice.
ELISA measurements of Aβ40 and Aβ42 at 2 and 4
months revealed no significant differences between con-
trol and TGF-β1 mice (Table 1, p = 0.78 in the 4-month-
old group), although at 9 months there was an increase
(102%) in Aβ40 levels (Table 1). FCA40 and 4G8 revealed
extensive plaque deposition in the parenchyma of the hip-
pocampus and cortex of over one-year-old APP mice (Fig
7A,7C), but produced no specific staining in TGF-β1 mice
at 4 or 9 months of age (Fig 7B,7D). The ELISA and the
immunohistochemical analysis combined suggest that
the thioflavin-S-labeled vascular deposits, which were
abundant at 4 months of age, contained no Aβ. Immuno-
histochemical analysis for SAP, which is considered a
common component of amyloid deposits [47], gave neg-
ative results (Fig 7E,7F). The SAP antibody has been
shown to detect mouse SAP by immunocytochemistry
[49].
The ELISA also showed that pioglitazone decreased by
23–32% the basal Aβ42 production in control and TGF-
β1 mice (Table 1, p = 0.013; 2-way ANOVA). Pioglitazone
GFAP immunohistochemistry in hippocampus Figure 3
GFAP immunohistochemistry in hippocampus. T-: control mice, T+: TGF-β1 mice. Animals had been fed for 2 months with 
control (A-B) or pioglitazone-containing (C, D) chow. GFAP expression was increased in TGF-β1 animals mostly in astrocytes 
in the dentate gyrus (DG) and in perivascular astrocytes at the hippocampal fissure (HiF). The astrocytosis was decreased by 
pioglitazone. Bars are 100 µM.
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had a negligible effect on Aβ40 – the ratio Aβ42/40 was
accordingly reduced – while ibuprofen had no effect on
the levels of Aβ40 or Aβ42.
Analysis of APP expression by Western blot showed sev-
eral bands around 100 kDa (Fig 8) that are probably post-
transcriptional modifications of the 695 amino acid-long
APP isoform predominant in brain. Neither the combined
nor the individual expression of APP bands was altered by
TGF-β1 over-expression at 4 or 9 months, or by treatment
with pioglitazone. Thus, the increase in Aβ40 detected at
9 months did not correlate with an increase in APP
expression.
Effect of pioglitazone on the hydrocephalus
TGF-β1 animals were hydrocephalic, reflected by an over
2-fold increase in ventricle surface assessed in coronal sec-
tions (p < 0.001) (Figs 9 and 10). Surprisingly,
pioglitazone increased the ventricle surface in non trans-
genic animals by 22% (p > 0.05), and exacerbated the
TGF-β1-induced increase by 55% (p < 0.001) (Figs 9 and
10). Although the effect of pioglitazone in control ani-
mals was not statistically significant when values at the
three brain levels were averaged, the drug caused a signif-
icant (p < 0.05) 40% increase at level 3, an area largely
comprising the ventrocaudal hippocampal horn (Fig
10G,10H). Conversely, pioglitazone acted rostrally in
TGF-β1 mice (110% increase at Bregma level 1) (Fig
10A,10B).
Discussion
The TGFβ1-mice used in this study showed between 2–4
months of age several of the pathological signs associated
with the anomalous expression of this cytokine in brain:
glia activation, vascular and meningeal deposition of a
material positive to thioflavin-S, and hydrocephalus.
Microglia activation was severely reduced at 9 months,
indicating that the cells became refractory to TGF-β1 stim-
ulation over time, whereas the thioflavin-S labeling, astro-
cytosis, and hydrocephalus persisted. Pioglitazone exerted
paradoxical actions on TGF-β1-elicited pathology: it
inhibited both astrocyte and microglia activation, but it
did not interfere with the vascular and meningeal deposi-
tions, and exacerbated the hydrocephalus. In addition,
pioglitazone decreased Aβ42 basal levels, an effect unre-
lated to the anti-inflammatory actions of the TZD since it
was equally observed in transgenic and controls, and the
latter do not display inflammation.
PPAR agonists are currently being considered as a treat-
ment of neurological diseases where chronic inflamma-
tion is suspected to be a pathogenic factor. There are NIH-
sponsored pilot clinical trials of TZDs ongoing for
Alzheimer's disease (Gary Landreth, personal communi-
cation) and multiple sclerosis (D.L. Feinstein, personal
Western blot analysis of GFAP expression in hippocampus Figure 4
Western blot analysis of GFAP expression in hippocampus. 
A) 4-month-old animals, treated for 2 months with control 
food or pioglitazone. B) 9-month-old mice. Values are the 
means ± SD; In A: (**) p < 0.01, (*) p < 0.05, two-way 
ANOVA analysis followed by Bonferroni analysis; n = 4–5 
per group. In B: (**) p < 0.01, Student's T-test; n = 5 per 
group.
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Thioflavin-S labeling in coronal brain sections Figure 5
Thioflavin-S labeling in coronal brain sections. A, B show hippocampus and C, D show cortex of 4-month-old mice; A, C are 
control mice, B, D, G are TGF-β1 mice, and E, F are a one-year-old APP mouse. Bars are 200 µm (A-D) or 100 µm (E-G). 
Thioflavin-positive material accumulated in the meninges and in vessels around the hippocampal fissure (HiF) in TGF-β1 mice. 
Vascular deposits in TGF-β1 mice were smoother in appearance and uniformly covered entire vascular segments, while in APP 
brains the deposits spread over the vessels in patches (compare E and F to G).
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Density of thioflavin-S positive vessels along the hippocampus Figure 6
Density of thioflavin-S positive vessels along the hippocampus. A) Evolution with age. B) Effect of anti-inflammatory drugs. Val-
ues are the means ± SD; (*) p < 0.05, ns=non significant, ANOVA and Bonferroni posthoc analyses. N = 4–6 mice per group. 
The vascular accumulation of thioflavin-S-positive material increases between 2–4 months, and it is not altered by pioglitazone 
or ibuprofen.
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communication), and GlaxoSmithKline has initiated a
clinical trial of pioglitazone in Europe for both Alzhe-
imer's disease and multiple sclerosis. The findings in the
present study are relevant to the clinical trials because
TGF-β1 animals display CAA-related vascular alterations
and dysfunction [3-6], and can develop a more severe
experimental allergic encephalomyelitis than normal
mice [31].
The observation that pioglitazone reduces glia activation
indicates that orally administered pioglitazone, like ibu-
profen, can traverse the blood-brain barrier and exert anti-
inflammatory actions in brain. This finding confirms the
pioglitazone-mediated decrease in glia activation reported
in the MPTP mouse model of Parkinson's disease [21].
Since activated microglia produce cytotoxic substances
[32], and astrogliosis leads to the dysregulation of
astrocyte-neuron networks [33], administration of piogli-
tazone may help to prevent the damage caused by chronic
glia activation.
Despite the decreased inflammation, pioglitazone exacer-
bated the hydrocephalus in TGF-β1 mice. It also increased
the ventricle size in normal animals. Hydrocephalus is a
salient feature of TGF-β1 homozygous transgenic mice
and, though to a lesser extent, heterozygous mice like the
ones generated for this study. That our mice were less
affected than the homozygous ones was indicated by the
lack of behavioral alterations clinically associated to
hydrocephalus such as aggression, or deficits in posture
and balance. TGF-β1 overproduction has been reported to
severely alter CSF dynamics, and studies indicate that the
underlying mechanism is obstruction of CSF clearance by
meningeal fibrosis [34,35]. Other examples exist of
hydrocephalus caused by growth factor-induced fibrosis
[36]. The site and mechanism of action of pioglitazone –
whether it stimulates CSF production or inhibits its reab-
sorption – remain to be investigated. Nevertheless TZDs
would not appear indicated for the treatment of diseases
presenting CSF flow alterations.
The anti-inflammatory drugs did not reverse the thiofla-
vin-S-positive vascular deposition. These deposits were
identified as Aβ by immunostaining with an array of anti-
bodies raised against human and rat Aβ proteins that
apparently stained vessels in a pattern identical to that
obtained with thioflavin-S [6]. At variance with this claim,
FCA40 and 4G8, antibodies that can recognize mouse Aβ
[27-29] produced no vascular labeling in the TGF-β1 mice
used in the present study. Also, the ELISA did not reveal
any change in the production of endogenous Aβ40 or
Aβ42 within 2–4 months, despite the unequivocal pres-
ence of vascular and meningeal thioflavin-S reactivity. It is
unlikely that these results were due to insufficient sensitiv-
ity of the techniques used, since the antibodies detected
Aβ deposition in APP transgenic mice, and these ELISAs
have been successfully used to measure very low levels of
endogenous murine Aβ [25,26]. Rather, these results,
together with the different appearance of vascular deposits
in APP and TGFβ-1 mice, strongly suggest that the thiofla-
vin-S-positive material is not Aβ. This is in agreement with
the view that spontaneous deposition of endogenous
mouse Aβ does not readily occur in the mouse brain [37].
An increase in Aβ40 was however detected in TGF-β1 mice
9 months old, suggesting changes in APP metabolism
later in the life of the animals. This finding reproduces in
part a study reporting up-regulation of APP mRNA and
protein, and increased production of Aβ40 and Aβ42 in 6-
month-old TGF-β1 heterozygous mice [38]. This and one
other study [39] also showed that TGF-β1 induces the
transcription of the APP gene, and the production of APP
and Aβ species in astrocyte cultures. Although these
studies demonstrate that TGF-β1 canstimulate the
Table 1: ELISA measurement of Aβ proteins in hippocampus
2 months 4 months 9 months
control control PIO IBU control
T- T+ T- T+ T- T+ T- T+ T- T+
Aβ40 9.8 ± 1.7 10.1 ± 1.1 9.5 ± 2.5 9.6 ± 2.1 8.5 ± 2.2 8.3 ± 1.5 9.9 ± 0.9 10.5 ± 2.0 9.2 18.6
Aβ42 7.2 ± 1.5 7.2 ± 1.0 6.8 ± 2.7 6.9 ± 1.7 5.2 ± 1.5* 4.7 ± 0.7* 7.2 ± 1.3 7.2 ± 1.8 6.5 7.8
ratio 42/40 0.74 0.71 0.71 0.73 0.61 0.57 0.73 0.68 0.71 0.42
n 6488656745
Values are means in fmol / mg protein ± SD, except at 9 months where measurements were performed in pooled hippocampi. Results: i) no 
difference between T+ and T- groups at 2 or 4 months; ii) increase in Aβ40 in T+ at 9 months; iii) decrease of basal Aβ42 but not Aβ40 by 
pioglitazone in T- and T+ groups (*) p = 0.013, PIO versus control, two-way ANOVA analysis; iv) no effect of Ibuprofen. n, number of animals, T-, 
non transgenic mice; T+, TGF-β1 mice.Journal of Neuroinflammation 2004, 1:11 http://www.jneuroinflammation.com/content/1/1/11
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synthesis and cleavage of glial APP, caution has to be
exerted when extrapolating this conclusion to an in vivo
context: the mice used in the present study produce TGF-
β1 constitutively since birth, while Aβ40 – and not Aβ42
– was detected only at midlife, in the absence of increased
APP expression. This indicates that factors other than TGF-
β1, or the amount of TGF-β1 produced, are of critical
importance in the regulation of APP metabolism in vivo.
Aβ and SAP immunoreactivity Figure 7
Aβ and SAP immunoreactivity. The images show coronal sections of hippocampi from over one-year old APP mice (A, C), a 4-
month-old TGF-β1 mouse (B) and a 9-month-old (D), stained with FC40 (A, B), 4G8 (C, D), thioflavin (E) or SAP (F). E, F are 
images of the same field in consecutive sections. FCA40 and 4G8 labeled Aβ plaques in APP mice and showed no specific reac-
tivity in TGF-β1 mice. No SAP was detected in the thioflavin-reactive vascular deposits. Bar equals 100 µm. CC: corpus callo-
sum. HiF: Hippocampal fissure; DG: dentate gyrus.
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Altogether, the present study supports a β amyloidogenic
effect of TGF-β1 in brain cells, but it provides no evidence
of vascular accumulation of Aβ peptides.
What is then the material labeled by thioflavin-S in TGF-
β1 mice Thioflavin is a recognized marker of "amyloid", a
term that applies to any protein that upon adopting a β-
pleated sheet configuration instead of the α-helical one
becomes fibrillar, insoluble, and precipitates [40]. Over
twenty proteins qualify as amyloids by the criterion of
thioflavin-S staining. Other than Aβ, amyloids to consider
are transthyretin, gelsolin, BRI, prion proteins or cystatin
C, which are prone to misfold and deposit in human
brain vessels and meninges, leading to several forms of
CAA [10,41]. Among possible mechanisms causing amy-
loid deposition in vessels, the one supported by postmor-
tem evidence in brains with Alzheimer's disease is altered
drainage of Aβ along periarterial interstitial fluid (ISF)
channels in the parenchyma and meninges [42,43]. By
analogy with Aβ, the precise location of thioflavin reactiv-
ity in meninges, penetrating arteries, and vessels in the
hippocampal fissure – also a "brain surface" – serves to
argue that TGFβ1 may impair the clearance of a given
protein and cause its deposition as an amyloid in brain. As
discussed for Aβ [43], local factors affecting the
production or solubility of the thioflavin-positive mate-
rial may contribute to its precipitation.
But arguments exist as well against the amyloid nature of
the thioflavin-reactive molecule. First, electron micros-
copy analysis revealed the presence in TGF-β over-express-
Western blot analysis of APP expression Figure 8
Western blot analysis of APP expression. A) 4-month-old 
mice, after treatment with pioglitazone; B) 9-month-old mice. 
Values are the means ± SD. N = 5–6 animals per group in A, 
and 5 in B. No change with genotype or treatment was 
observed.
0
20
40
60
80
100
120
140
A
P
P
 
e
x
p
r
e
s
s
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
Control PIO
Control
TGFβ
APP A
B
0
20
40
60
80
100
120
140
Control
TGFβ
A
P
P
 
e
x
p
r
e
s
s
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
APP
Effect of pioglitazone on ventricle size Figure 9
Effect of pioglitazone on ventricle size. Values are the means 
± SD of ventricle surfaces at three bregma levels. (ns) non 
significant, (***) p < 0.001, two-way ANOVA analysis, Bon-
ferroni post hoc. N = 10–12 animals per group.
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Zone-dependence of the effect of pioglitazone on ventricle size Figure 10
Zone-dependence of the effect of pioglitazone on ventricle size. A, B show rostral, C-F, mid-; and G, H dorsal brain sections. 
Pioglitazone increased ventricle volumes dorsally in non transgenic mice (T-) (compare H to G), while the effect on TGF-β1 
mice (T+) was more apparent rostrally (compare B to A).
Control PIO
T+ T+
T+ T+
T- T-
T- T-
AB
C
E
GH
F
DJournal of Neuroinflammation 2004, 1:11 http://www.jneuroinflammation.com/content/1/1/11
Page 15 of 17
(page number not for citation purposes)
ing brains of vascular deposits that do not display [44] the
fibrillar structure quintessential to amyloids [45]. Second,
SAP was not detected in the vascular deposits by
immunocytochemistry. SAP is a non-fibrillar pentraxin
plasma protein that contributes to amyloidosis by stabi-
lizing amyloid fibrils, and is widely considered as a com-
mon component of amyloid deposits [46]. The latter tenet
may, however, not apply to brain. SAP is not produced by
brain cells, and the association to Aβ plaques in Alzhe-
imer's disease is probably the result of blood-brain barrier
damage [47], which may not occur in animal models.
Accordingly, SAP has not been detected in plaques from
APP-overexpressing brains [48], a result confirmed by our
laboratory (data not shown). Thus, the absence of SAP in
TGF-β1 brains does not unequivocally prove that the vas-
cular deposit is not amyloid.
We thus conclude that the thioflavin-positive material has
the tinctorial properties and clearance routes of an amy-
loid, but there is no direct evidence that it is such.
Whatever the nature of the vascular material, we speculate
that the lack of effect of pioglitazone on its deposition is
related to the increase in hydrocephalus caused by the
TZD. Since a continuity exists between ISF and CSF, alter-
ations of flow in either compartment would be transmit-
ted to the other [49]. Hence, in worsening the TGF-β1-
induced alteration of CSF dynamics, pioglitazone would
impair the ISF drainage of the yet unidentified substance
thus promoting – or not preventing – its deposition in
meninges and vessels around the hippocampal fissure. If
so, pioglitazone may not be beneficial for the treatment of
diseases that are caused to some extent by altered vascular
drainage of amyloid-like proteins.
Finally, pioglitazone, but not ibuprofen, selectively
decreased the content of the allegedly more toxic Aβ42,
while not altering that of Aβ40, thus causing a change in
the Aβ42/40 ratio. This evidence supports a novel effect of
PPARγ activation on Aβ metabolism independent of
inflammation. The possible therapeutic relevance of this
phenomenon lies in the nature of the Aβ measured that is:
i) endogenous, ii) wild type, and iii) soluble, for the ani-
mals under study have no Aβ deposits. An effect on wild
type Aβ production may render PPARγ agonists appropri-
ate for the treatment of the more common non familial
forms of Alzheimer's disease. An effect on soluble Aβ
gains importance in light of recent studies suggesting that
cognitive dysfunction in Alzheimer's disease may corre-
late better with soluble than insoluble levels of Aβ [50].
The parallel finding that APP expression was not changed
by pioglitazone rules out that the Aβ42 reduction was
caused by a decrease in APP production. Rather, the TZD
may act on the production or degradation of Aβ42. Also
ibuprofen has been shown to reduce plaque-associated
and soluble Aβ42 in mice over-expressing the Swedish
mutation of human APP [15,16]. The lack of effect of ibu-
profen in our model could be due to a preferential action
of NSAIDs on the metabolism of mutated Aβ. Interest-
ingly, a selective action on Aβ42 forms appears to be the
rule amongst anti-inflammatory drugs. This calls into
question the use of NSAIDs or TZDs for the treatment of
Aβ-related CAA caused by Aβ40 deposition [51].
Conclusions
In summary, the present study: i) supports β amyloidog-
enic actions of TGF-β1 in brain (i.e. increased production
of Aβ40), but provides no evidence of vascular
accumulation of Aβ peptides, ii) shows that TGF-β1 over-
expression results in the early deposition in vessels and
meninges of a thioflavin-S-positive molecule yet to iden-
tify; and iii) reveals a mix of potentially beneficial (i.e.
decrease of chronic glia activation and reduction of basal
Aβ42 levels) and detrimental actions (i.e. increased
hydrocephalus, and lack of effect on thioflavin-S-positive
deposits) of pioglitazone that will have to be weighed
when considering the therapeutic applications of this
TZD.
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